Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Nick Cross

Bent Jakobsen

Immunocore Holdings plc

Genenta Science is a clinical stage immuno-oncology company developing a cell-based platform that harnesses the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. The platform is not restricted by tumor type or target antigen and enables sustained targeted expression of therapeutic payloads inside the tumor microenvironment.

Genenta Science

Mapi Pharma is a clinical stage pharmaceutical company that develops complex active pharmaceutical ingredients and proprietary pharmaceuticals, including long acting depot injectable drugs.

Mapi Pharma

Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. 

See our community guidelines: http://bit.ly/2kFA8hr

Oxford Finance LLC

General Atlantic

Rock Springs Capital

RTW Investments

WuXi AppTec

Bill & Melinda Gates Foundation

Terra Magnum Capital Partners (""""TMCP"""")""

CCB International

JDRF T1D Fund

BlackRock

Immunocore

Unhealthy cells have evolved mechanisms for evading T cells, making diseases like cancer harder to treat. 

ImmTAC molecules contain a T cell receptor that has been engineered to better recognise its target and seek out evading cells. #IMCRSharing #innovation

It is by living our values daily that we are able to develop transformative treatments and to innovate for patients. #WeAreIMCR #innovation #ResearchAndDevelopment

Looking to advance your career in Regulatory Affairs? Apply for our Regulatory Submissions Manager position and grow within a highly innovative, agile, and entrepreneurial environment. https://lnkd.in/eu7WxW_v #WeAreIMCR #hiring #biotechjobs

Gynecologic cancers account for nearly 40% of cancer cases & 1/3 of cancer deaths in women. We must continue the search for new treatments & prevention measures to save the lives of women across the globe. #CervicalCancerPreventionWeek #CervicalCancerAwarenessMonth #WeAreIMCR

Come and apply the principles of effective clinical project practices at a pioneering biotech. #WeAreIMCR #biotechjobs #hiring
https://lnkd.in/eTSVJJcC

Metric
Company Name	Immunocore Holdings plc	Genenta Science	Mapi Pharma
Symbol	IMCR
MSH ID	COM:IMMUNOCORE	COM:GENENTA	COM:MAPI-PHARMA
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Pharmaceuticals
Country	GB	IT	IL
Stage			Corporate Round
Employee Count	497
Website	immunocore.com	genenta.com	mapi-pharma.com
LinkedIn	immunocore
Founders

Metric
Market Cap	1.90B
Enterprise Value
Monthly Web Traffic	6.81K	612
Web Traffic Growth	-0.38
Valuation
Raised Capital	350M	20M

Metric
Revenue	249.43M
Revenue (LTM)
Revenue (NTM)
Gross Profit	248.39M
EBITDA	-38.47M
Operating Income	-59.65M
Net Income	-55.29M
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1.00
Operating Profit Margin	-0.22
EBITDA Margin	-0.15
Net Profit Margin	-0.19
Return on Equity	-0.17
Return on Assets	-0.06
Return on Capital Employed	-0.08

COM:IMMUNOCORE

Immunocore Holdings plc

Last Close

32.12

22/11 21:00

Market Cap

1.90B

Beta: -

Volume Today

190.00K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-53.27
P/B Ratio	9.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.95
EV Multiple	-46.28

Metric
Days Sales Outstanding	94.90
Days Payables Outstanding	2.93K
Days Inventory Outstanding	1.58K
Operating Cycle	1.67K
Cash Conversion Cycle	-2.98K
Asset Turnover	0.42

Metric
Operating Cash Flow	2.94M
Free Cash Flow	-2.48M
Cash Flow to Debt	0.04
Operating Cash Flow/Sales	0.05
Free Cash Flow Yield	0.00

Metric
Cash & Equivalents	442.63M
Accounts Receivable	-17.87M
Inventory	4.50M
Goodwill
Debt to Capitalization	0.57
Debt to Assets	0.15
Current Ratio	4.26
Quick Ratio	5.94

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.14
R&D to Revenue	0.60
SG&A to Revenue	0.24